SLC6A5 encodes Glycine Transporter 1 (GlyT1), a sodium/chloride-dependent glycine transporter primarily expressed in astrocytes and endothelial cells of the blood-brain barrier. GlyT1 plays a critical role in terminating glycinergic neurotransmission, maintaining extracellular glycine concentrations, and regulating the balance between excitatory and inhibitory signaling in the central nervous system[1][2].
The SLC6A5 locus is on chromosome 11p15.5 and encodes a 12-transmembrane-domain protein of approximately 635 amino acids. GlyT1 is distinct from GlyT2 (SLC6A9) in its ionic coupling (Na+/Cl- dependence), tissue distribution, and physiologic function. While GlyT2 is primarily presynaptic and mediates glycine reuptake at inhibitory synapses, GlyT1 is largely extrasynaptic and controls ambient extracellular glycine levels that modulate both glycinergic and NMDA receptor-mediated glutamatergic signaling[3].
SLC6A5 encodes a prototypical SLC6 family member with the canonical 12-transmembrane helix topology:
GlyT1 operates via an alternating access mechanism coupling glycine transport to the electrochemical gradients of Na+ and Cl-:
This transport cycle is electrogenic (net +1 charge per glycine molecule) and can be modulated by multiple regulatory inputs including phosphorylation, glycosylation, and protein-protein interactions[4].
GlyT1 is essential for clearing glycine from the synaptic cleft following glycinergic neurotransmission. At brainstem and spinal cord inhibitory synapses, GlyT1 (primarily the GlyT2 isoform in presynaptic terminals) terminates synaptic signaling by reuptake. However, GlyT1's role is distinct: it maintains ambient extracellular glycine levels that influence:
Astrocytic GlyT1 is strategically positioned to:
A distinctive feature of GlyT1 is its expression in brain microvascular endothelial cells forming the blood-brain barrier (BBB). Here, GlyT1 mediates glycine transport across the BBB and contributes to the selective permeability of amino acid neurotransmitters. This has therapeutic implications for drug delivery targeting glycineergic systems.
Hyperekplexia, also known as startle disease or stiff baby syndrome, is a rare neurodevelopmental disorder characterized by exaggerated startle responses, hypertonia in infancy, and episodic falling. SLC6A5 is one of several genes (along with GLRA1, GLRB, and SLC6A9) where pathogenic variants cause hyperekplexia[5][6].
Mechanistic basis:
Genotype-phenotype correlations:
SLC6A5 variants are associated with early-onset epilepsy, particularly in patients with comorbid hyperekplexia. The mechanistic link involves disrupted glycinergic inhibition during critical developmental periods, leading to hyperexcitability and seizure susceptibility. Animal models show that GlyT1 knockout produces spontaneous seizures and early mortality[4:1].
By controlling extracellular glycine levels, GlyT1 indirectly regulates NMDA receptor activity. This connection is relevant to:
GlyT1 is a therapeutic target in multiple CNS disorders:
| Disorder | Therapeutic Rationale | Status |
|---|---|---|
| Schizophrenia | GlyT1 inhibition increases glycine for NMDA co-agonism | Clinical trials (failed) |
| Stroke/TBI | GlyT1 inhibition reduces excitotoxicity | Preclinical |
| Hyperekplexia | Gene therapy to restore transport | Preclinical |
| ADHD | GlyT1 modulators for prefrontal function | Research |
SLC6A5 pathogenic variants include:
SLC6A5-associated hyperekplexia follows autosomal recessive inheritance, consistent with the requirement for biallelic loss-of-function to produce the phenotype. Heterozygous carriers are typically asymptomatic but may show subtle endophenotypes.
SLC6A5 shows constraint against loss-of-function variation. The gene has a low pLI score and elevated missense Z-score, indicating evolutionary constraint on functional disruption.
GlyT1 shares structural homology with other SLC6 family members including:
The bacterial leucine transporter (LeuT) serves as a structural model for the entire family. Cryo-EM structures of human GlyT1 have revealed:
Several GlyT1 inhibitor classes have been developed:
SLC6A5 sequencing is included in hyperekplexia gene panels. Diagnostic yield is approximately 5-10% of clinically diagnosed hyperekplexia cases, with GLRA1 being the more commonly mutated gene.
The GlyT1 field has faced significant translational challenges:
SLC6A5 encodes GlyT1, the sodium/chloride-dependent glycine transporter essential for glycinergic neurotransmission and NMDA receptor co-agonism. The gene is primarily associated with hyperekplexia and epilepsy, where loss-of-function variants cause excessive glycinergic inhibition and network hyperexcitability. GlyT1's expression in astrocytes and blood-brain barrier endothelial cells makes it a unique therapeutic target at the intersection of inhibitory and excitatory neurotransmission.
Key aspects for neurodegeneration research include:
Disease mechanisms: SLC6A5 variants cause monogenic hyperekplexia with epilepsy, demonstrating the importance of glycine homeostasis in motor control and seizure threshold.
Therapeutic target: GlyT1 inhibition has been explored for schizophrenia and excitotoxic conditions, though clinical translation remains challenging.
Research tools: Animal models, structural data, and functional assays enable variant interpretation and drug discovery.
Clinical genetics: Autosomal recessive inheritance with a spectrum of severity based on variant class.
: Broer S, Broer A. The sodium-dependent chloride-coupled neurotransmitter transporter family SLC6. 2021. ↩︎
: Kristensen AS, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. 2011. ↩︎
: Zafra F, et al. Glycine transporter 1: a key modulator of excitatory-inhibitory balance in the CNS. 2017. ↩︎
: Biche J, et al. GlyT1 in synaptic development and neurological disorders. 2023. ↩︎ ↩︎
: Hirano K, et al. SLC6A5-associated hyperekplexia: genotype-phenotype correlation. 2020. ↩︎
: Raas-Rothschild A, et al. Hyperekplexia and epilepsy: clinical spectrum and genetics. 2021. ↩︎